Investor Presentaiton

Hospital: Contributions from key products bridion (sugammadex) 100 mg/mL Injection BRIDION sales of $424M were flat as greater share among neuromuscular blockade reversal agents in the U.S. was offset by the impact of generic entry primarily in Europe PREVYMIS sales grew 38% driven by continued strong global demand Growth rates exclude the impact of foreign exchange. $423M $369M +15% +22% $424M +0% 3Q21 3Q22 3Q23 0000000 $96M +22% PREVYMIS (letermovir) 240 mg, 480 mg tablets Injection 20 mg/mL $114M +29% $157M +38% 3Q21 3Q22 3Q23 MERCK 14

View entire presentation